Dravet syndrome
MONDO:0100135Dravet syndrome is a channelopathy with epilepsy of with onset during the first year of life, typically 4-5 months, characterized by status epilepticus and a variety of drug-resistant seizures often induced by fever, presenting in previously healthy children, and which frequently leads to cognitive and motor impairment. Dravet differs from other channelopathies usually due to a mutation in SCN1A.
Also known as: DS, Dravet, Dravet syndrome, SME, SMEB, myoclonic epilepsy, severe, of infancy, severe myoclonic epilepsy of infancy
52 clinical trials for this condition and its sub-types, 39 tagged with Dravet syndrome itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →-
New hope for infants with severe epilepsy: fenfluramine trial launches
Disease control CompletedThis phase 3 trial is testing the safety and tolerability of fenfluramine (Fintepla) in 25 infants aged 1 to 2 years with Dravet syndrome, a severe form of epilepsy. The drug is given as an oral solution twice daily alongside other seizure medications. Researchers will monitor he…
Phase 3 • Sponsor: UCB BIOSCIENCES, Inc. • Aim: Disease control
Last updated Sep 19, 2026 00:00 UTC
-
Can a new drug curb seizures in children with severe epilepsy?
Disease control CompletedResearchers are testing an experimental drug called TAK-935 in children aged 2 to 17 with Dravet syndrome or Lennox-Gastaut syndrome, two severe forms of epilepsy that often resist treatment. The trial compares TAK-935 added to standard anti-seizure medications against a placebo …
Phase 2 • Sponsor: Takeda • Aim: Disease control
Last updated Sep 16, 2026 00:00 UTC
-
Can a new Add-On drug tame seizures in dravet syndrome?
Disease control CompletedThis phase 3 trial tests whether soticlestat, an experimental oral drug, can reduce convulsive seizures in children and young adults with Dravet syndrome, a severe form of epilepsy. Participants continue their standard antiseizure therapy and also receive either soticlestat or a …
Phase 3 • Sponsor: Takeda • Aim: Disease control
Last updated Sep 06, 2026 00:00 UTC
-
New epilepsy drug shows promise in long-term safety trial
Disease control CompletedThis study tested the long-term safety of a drug called LP352 (bexicaserin) in 41 people aged 12 to 65 with severe epilepsy syndromes like Dravet or Lennox-Gastaut. Participants took the drug three times daily for up to 52 weeks. The main goal was to check for side effects, while…
Phase 2 • Sponsor: Longboard Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 08:01 UTC
-
New hope for rare seizure patients: Long-Term drug safety confirmed
Disease control CompletedThis study looked at the long-term safety of a drug called fenfluramine (ZX008) for people with rare seizure disorders like Dravet syndrome and Lennox-Gastaut syndrome. A total of 412 participants who had completed earlier studies took the drug and were monitored for side effects…
Phase 3 • Sponsor: Zogenix, Inc. • Aim: Disease control
Last updated Jun 27, 2026 07:58 UTC
-
Routine EEGs may hold hidden clues to childhood epilepsy — a new analysis method is put to the test
Diagnosis CompletedThis study is testing whether a computer tool called BioEP can detect signs of seizure susceptibility in standard EEG recordings from children with epilepsy. Researchers will analyze past EEGs from 530 children aged 2 to 18 who already have an epilepsy diagnosis. The goal is to s…
Sponsor: Neuronostics Ltd • Aim: Diagnosis
Last updated Aug 01, 2026 00:00 UTC
-
New drug candidate TAK-935 tested for Hard-to-Treat epileptic encephalopathies
Symptom relief CompletedResearchers are testing an experimental drug called TAK-935 in adults with developmental and/or epileptic encephalopathies, severe brain conditions that cause frequent seizures and developmental problems. The trial enrolls a small number of participants who continue their regular…
Phase 1/2 • Sponsor: Takeda • Aim: Symptom relief
Last updated Sep 16, 2026 00:00 UTC
-
Virtual therapy helps kids with rare epilepsy gain daily living skills
Symptom relief CompletedThis study tested whether remote occupational therapy could help children and teens (ages 7-18) with Dravet syndrome improve their daily living skills and satisfaction. 14 families participated in online sessions where a therapist coached the child or parent. The goal was to see …
Sponsor: Fondazione Policlinico Universitario Agostino Gemelli IRCCS • Aim: Symptom relief
Last updated Jun 27, 2026 12:34 UTC
-
New parent support programme shows promise for families of children with complex needs
Symptom relief CompletedThis pilot study tested a community-based group programme called 'Encompass' for parents of children under 5 with complex neurodisability. Fifteen parents in East London attended ten group sessions over six months. The study aimed to see if the programme was feasible and acceptab…
Sponsor: City, University of London • Aim: Symptom relief
Last updated Jun 27, 2026 12:05 UTC
-
How many people live with rare epilepsies in spain? a nationwide count aims to find out
Knowledge-focused CompletedThis study looks at medical records from public hospitals in Spain to count how many children, teenagers, and adults have Dravet syndrome or Lennox-Gastaut syndrome, and how many new cases are diagnosed each year. It is an observational study, meaning no treatment or intervention…
Sponsor: Takeda • Aim: Knowledge-focused
Last updated Aug 20, 2026 00:00 UTC
-
Liquid vs. pill: new study tests easier way to take seizure drug
Knowledge-focused CompletedThis study tested two versions of the seizure medication stiripentol (Diacomit®) in 24 healthy adults: a capsule and a liquid suspension. The goal was to see if the liquid form is absorbed by the body in a similar way to the capsule. If so, it could provide a more convenient opti…
Phase 1 • Sponsor: Biocodex • Aim: Knowledge-focused
Last updated Jun 26, 2026 18:16 UTC